Neurocrine Biosciences Inc(NBIX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL ? Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.

Current Price

$91.04

RSI

33.623

Beta:

0.786541

February 05, 2021
412.3M
84.8M

1.557 %
16.261 %
8.031 %
-9.653 %

$994,700,000
$756,100,000
$420,700,000
$161,626,000
$15,000,000
$19,769,000
31.557 %
79.724 %
160.292 %
977.507 %
-31.793 %

$106,700,000
$46,500,000
$21,800,000
$-142,542,000
$-141,090,000
$-88,929,000
129.462 %
113.303 %
753.862 %
-1.019 %
-36.970 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.